Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study
Pablo Tolosa(Research Institute Hospital 12 de Octubre), Eva Ciruelos(Research Institute Hospital 12 de Octubre), Juan Miguel Cejalvo(Universitat de València), Manuel Alva(Hospital Universitario 12 De Octubre), Guillermo Villacampa(Vall d'Hebron Institut de Recerca), Maria Angeles Cobos(Research Institute Hospital 12 de Octubre), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Ana Maria Roncero(Hospital Universitario 12 De Octubre), Lucía Parrilla, Javier David Benítez Fuentes(Universidad de Zaragoza), Isabel García-Fructuoso(Breast Cancer Research Foundation), Sònia Servitja(Hospital Del Mar), Laura Lema(Hospital Universitario 12 De Octubre), María Fernández Abad(Hospital Universitario Ramón y Cajal), Karla Alejandra Lopez(Instituto Nacional de Cancerología), A. Prat(Cancer Clinic), Tomás Pascual(Cancer Clinic), I. Diaz(Research Institute Hospital 12 de Octubre), Olga Martínez-Sáez(Hospital Clínic de Barcelona), Ester Sanfeliu(Hospital Clínic de Barcelona), Agustín Sánchez-Belmonte(Centro de Investigación Biomédica en Red de Cáncer), Marcos Malumbres(Institució Catalana de Recerca i Estudis Avançats), Fara Brasó-Maristany(Hospital Clínic de Barcelona), Fernando Salvador(Institute for Research in Biomedicine), Yolanda Ruano(Hospital Virgen de la Salud)
Cited by 0
Related Papers
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
|EMBO Molecular Medicine|2018|271
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial
|Neuro-Oncology|2022|247
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
|The Lancet|2023|225
Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer
|Cancer Discovery|2020|183
Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and <i>BRAF</i> <i>V600E</i> mutation
|The Journal of Experimental Medicine|2019|136